Taiyo Considers Generics Collaboration With Foreign Drug Makers
This article was originally published in PharmAsia News
After Nichi-Iko and Sanofi-Aventis announced a joint venture agreement, Nagoya-based Taiyo Pharmaceutical is also considering collaborating with a foreign drug maker to expand the generics market in Japan, Senior Exec Makoto Shimada disclosed in at a May 28 press briefing
You may also be interested in...
Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While its basic science is plausible, its best-in-class claims are bound to generate skepticism.
In the first of a two-part article on transparency provisions for the new EU clinical trial portal, the Pink Sheet reports on aspects that sponsors must consider to protect commercially confidential information in their clinical trial applications. The second article will look at the approach taken by Merck and discuss outstanding hot topics in relation to transparency and CTIS.
EU and UK regulators are vying for vaccine filings, and the EMA will consider changing the terms of the marketing authorization for remdesivir after a WHO panel advised against its use in COVID-19. An Austrian biotech firm is investigating the prophylactic potential of a carrageenan-based spray.